Drug interactions
Linagliptin-metformin + Octreotide
Severity: Moderate
Linagliptin-metformin and Octreotide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Octreotide suppresses insulin, glucagon and growth hormone secretion, so it can cause either hyperglycemia or hypoglycemia. This can destabilise glucose control in patients on antidiabetic therapy.
What this interaction means in plain words
Linagliptin-metformin and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Linagliptin-metformin belongs to Endocrine; Octreotide belongs to Endocrine.
Why it happens
Somatostatin analogue inhibition of insulin and counter-regulatory hormone secretion produces unpredictable glycemic effects.
What to do
Monitor blood glucose closely when starting, changing or stopping octreotide and adjust antidiabetic therapy accordingly.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Linagliptin-metformin and Octreotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Octreotide
Frequently asked questions
Can I take Linagliptin-metformin with Octreotide?
MediHelp rates the interaction as moderate. Linagliptin-metformin and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Octreotide suppresses insulin, glucagon and growth hormone secretion, so it can cause either hyperglycemia or hypoglycemia. This can destabilise glucose control in patients on antidiabetic therapy.
How serious is the interaction between Linagliptin-metformin and Octreotide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose closely when starting, changing or stopping octreotide and adjust antidiabetic therapy accordingly.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
